FILING BY EXPRESS MAIL UNDER 37 CFR 1.10

EV 485023535 US September

16. Other items or information: Application Dat Sheet

September 7, 2004

Date of Deposit

Form PTO-1390-MOD U. (REV 10-96)	S. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER
(KEV 10-90)		DV/4-32408A
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
		Not Yet Assigned
		10/506822
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP 03/02565	12 March 2003 (12.03.03)	13 March 2002 (13.03.02)
TITLE OF INVENTION		
PHARMACEUTICAL MICROPARTICLES		•
APPLICANT(S) FOR DO/EO/US		
AUSBORN ET AL.		
Applicant herewith submits to the United States I	Designated/Elected Office (DO/EO/US) tl	he following items and other information:
	- ,	-
•		

App	licar	at herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:
1. 2. 3.		This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.  This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.  This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.	$\boxtimes$	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priorit date.
5.	$\boxtimes$	A copy of the International Application as filed (35 U.S.C. 371(c)(2))  a.
6. 7.		c. is not required, as the application was filed in the United States Receiving Office (RO/US).  A translation of the International Application into English (35 U.S.C. 371(c)(2)).  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).  a. are transmitted herewith (required only if not transmitted by the International Bureau).  b. have been transmitted by the International Bureau.
8. 9. 10.		c.  have not been made; however, the time limit for making such amendments has NOT expired. d.  have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
lten	ns 1	1. to 16. below concern document(s) or information included.
11.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13.	$\square$	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.
14.		A substitute specification.
15.		A change of power of attorney and/or address letter.

U.S. APPLICATION NO. (If known, see 37 CFR 15) P INTERNATIONAL APPLICATION NO.  Not Yet Assigned ( C C C C C C C C C C C C C C C C C C					
17.   The following fees are submitted:	CALCULATIONS PTO USE ONLY				
BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):					
Search Report has been prepared by the EPO or JPO					
International preliminary examination fee paid to USPTO (37 CFR 1.482)					
No international preliminary examination fee paid to USPTO (37 CFR 1.482)					
but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$770					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,080					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)					
ENTER APPROPRIATE BASIC FEE AMOUNT =	\$ 920				
Surcharge of \$130 for furnishing the oath of declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$				
CLAIMS NUMBER FILED NUMBER EXTRA RATE					
	\$				
	\$				
	\$				
TOTAL OF ABOVE CALCULATIONS = \$ 920					
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).	s .				
	\$ 920				
Processing fee of \$130 for furnishing the English translation later than 20 30 months from					
· · · · · · · · · · · · · · · · · · ·	\$ \$ 920				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied					
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property + \$					
TOTAL FEES ENCLOSED =	\$ 920				
	Amount to be: \$				
<b>-</b>	refunded \$				
a. A check in the amount of \$ to cover the above fees is enclosed.	charged   #				
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$920 to cover the above fees. A					
duplicate copy of this form is enclosed.  c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to					
Deposit Account No. 19-0134 in the name of Novartis.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
Send all correspondence to the address associated with Customer No. 001095, which is currently:					
Thomas Hoxie John W. Kung					
Novartis Attorney for Applicants					
Corporate Intellectual Property Reg. No. 44,199					
One Health Plaza, Building 430 (862) 778-7877					
East Hanover, NJ 07936-1080					